...
首页> 外文期刊>Japanese Journal of Pharmacology >In Vitro Receptor Binding and In Vivo Receptor Occupancy in Rat and Guinea Pig Brain: Risperidone Compared with Antipsychotics Hitherto Used
【24h】

In Vitro Receptor Binding and In Vivo Receptor Occupancy in Rat and Guinea Pig Brain: Risperidone Compared with Antipsychotics Hitherto Used

机译:大鼠和豚鼠脑中的体外受体结合和体内受体占有率:利培酮与迄今使用的抗精神病药比较

获取原文

摘要

References(73) Cited-By(59) Risperidone was compared with antipsychotics hitherto used for in vitro receptor binding using animal brain or cloned (human) receptors and in vivo receptor occupancy in rat and guinea pig brain following acute treatment. Both in vitro and in vivo, risperidone, 9-OH-risperidone, SM-9018, clozapine and clocapramine showed higher affinity for 5-HT2A- than for D2-receptors, whereas mosapramine, haloperidol, bromperidol and nemonapride had a slight to strong preference for D2- compared to 5-HT2A-receptors. In vivo, risperidone showed the highest potency for 5-HT2A-receptor occupancy; To obtain the same extent of D2-receptor occupancy, a 19-times higher dosage was required. 9-OH-Risperidone, the principal active metabolite of risperidone, showed a receptor occupancy profile comparable to that of risperidone. No regional selectivity for D2-receptor occupancy in mesolimbic vs nigrostriatal areas was detected for any of the compounds. Risperidone differed from the other compounds by the remarkably shallow slope of its D2-receptor dose-occupancy curve. A greater predominance of 5-HT2A-receptor vs D2-receptor occupancy and a more gradual occupancy of D2A-receptors differentiate risperidone from the other compounds. Both properties probably assist in preventing an extensive blockade of D2-receptors, the cause for extrapyramidal symptoms (EPS). The predominant 5-HT2A-receptor occupancy most likely underlies risperidone''s beneficial effects on the negative symptoms of schizophrenia and an adequately low D2-receptor occupancy adds to the treatment of positive symptoms with a low liability of EPS.
机译:参考文献(73)Cited-By(59)将利培酮与迄今为止使用抗精神病药进行体外受体结合(使用动物脑或克隆(人)受体进行体外受体结合)和急性治疗后大鼠和豚鼠脑中的体内受体占有率进行了比较。在体外和体内,利培酮,9-OH-利培酮,SM-9018,氯氮平和氯卡帕明对5-HT2A-的亲和力均高于对D2受体的亲和力,而莫沙帕明,氟哌啶醇,溴吡哌和尼莫那必利则有轻微至强烈的偏爱D2-与5-HT2A受体相比。在体内,利培酮对5-HT2A-受体的占有率最高。为了获得相同程度的D2受体占有率,需要19倍的高剂量。利培酮的主要活性代谢物9-OH-利培酮显示出与利培酮相当的受体占有率。对于任何一种化合物,均未检测到中边缘边缘区与黑纹状体区中D2受体占据的区域选择性。利培酮与其他化合物的区别在于其D2受体剂量-吸收曲线的斜率非常浅。 5-HT2A受体的占有率比D2受体的占有率更高,而D2A受体的逐渐占据率则使利培酮与其他化合物区别开来。这两个特性可能有助于防止D2受体的广泛阻断,D2受体是锥体束外症状(EPS)的起因。 5-HT2A受体占主要地位,很可能是利培酮对精神分裂症阴性症状的有益作用,而D2受体充分低则增加了对阳性症状的治疗,而EPS的责任较低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号